Comorbidities (determined through linkage with the DNPR) and use of medications (determined through linkage with the DNHSP) at enrolment among the first 7011* patients with newly diagnosed type 2 diabetes enrolled in the DD2 project
| Variables | Patients with type 2 diabetes |
| Persons enrolled in DD2 by February 2016, n (%) | 7011 (100) |
| Charlson Comorbidity Index score† | |
| 0 | 4807 (69) |
| 1–2 | 1820 (26) |
| 3+ | 384 (5) |
| Charlson Comorbidity Index conditions at baseline, n (%) | |
| Myocardial infarction | 345 (5) |
| Congestive heart failure | 283 (4) |
| Peripheral vascular disease | 309 (4) |
| Cerebrovascular disease | 465 (7) |
| Dementia | 13 (0.2) |
| Chronic pulmonary disease | 510 (7) |
| Connective tissue disease | 183 (3) |
| Ulcer disease | 126 (2) |
| Mild liver disease | 111 (2) |
| Hemiplegia | 19 (0.3) |
| Moderate to severe renal disease | 117 (2) |
| Any tumour | 508 (7) |
| Leukaemia | 15 (0.2) |
| Lymphoma | 26 (0.4) |
| Moderate to severe liver disease | 16 (0.2) |
| Metastatic solid tumour | 43 (0.6) |
| HIV/AIDS | 9 (0.1) |
| Any macrovascular complications | 1511 (22) |
| Any microvascular complications | 1035 (15) |
| Diabetic neuropathy | 230 (3) |
| Diabetic retinopathy | 682 (10) |
| Diabetic nephropathy | 209 (3) |
| Mental disorder (based on discharge and treatment codes for mental illness)* | 1456 (21) |
| Antidiabetic treatment, n (%)*‡ | |
| Insulin only | 80 (1) |
| Insulin and oral antidiabetic treatment | 396 (6) |
| Oral antidiabetic treatment | 5387 (78) |
| None | 1053 (15) |
| Glucose-lowering drugs, n (%)*‡ | |
| Biguanides (metformin) | 5631 (81) |
| Insulin | 476 (7) |
| Sulfonylureas | 463 (7) |
| DPP-4 inhibitors | 653 (9) |
| GLP-1 analogues | 378 (5) |
| SGLT-2 inhibitors | 57 (0.8) |
| Meglitinides | 7 (0.1) |
| Thiazolidinediones (glitazones) | 1 (0.01) |
| Alpha-glucosidase inhibitors | 4 (0.06) |
| Antihypertensive treatment excluding loopdiuretics, n (%)*‡ | 4991 (72) |
| ACE inhibitors or ATII-antagonist treatment, n (%)*‡ | 4157 (60) |
| Hypolipidaemic treatment, n (%)*‡ | 4886 (71) |
| Oral steroids, n (%)*‡ | 430 (6) |
*At the time of analysis, full prescription data were available only until 31 December 2015. Therefore, variables based on data from the DNHSP are for a subcohort numbering 6916 patients.
†Diabetes mellitus not included in the score as it constitutes the index disease. Comorbidity categories include DNPR derived data on cancer; more detailed cancer data are available from the Danish Cancer Registry.
‡Within the last year prior to DD2 enrolment.
ATII-antagonist, angiotensin 2 antagonist; DD2, Danish Centre for Strategic Research in Type 2 Diabetes; DNPR, Danish National Patient Registry; DNHSP, Danish National Health Service Prescription; DPP-4-inhibitors, dipeptidylpeptidase 4 inhibitors; GLP-1 analogues, glucagon-like peptide 1 analogues; SGLT-2 inhibitors, sodium glucose cotransporter 2 inhibitors.